Evercore ISI raises BridgeBio Pharma price target on Attruby sales

Evercore ISI raised BridgeBio Pharma’s price target to $130 from $125 and reiterated an Outperform rating, citing stronger Attruby commercialization, a tafamidis settlement that delays generic competition until 2031, and a $500 million share buyback. Q1 2026 results were mixed: EPS missed at -$0.84 versus -$0.6809 consensus, but revenue beat at $194.5 million versus $178.16 million. The company also highlighted a 2.77 current ratio, 126% trailing revenue growth, and over $4 billion of peak sales potential for Attruby.

Analysis

BBIO is starting to look less like a science-risk story and more like a commercialization-and-capital-allocation story, which usually deserves a multiple re-rate if execution stays clean. The key second-order effect is that the buyback signals management believes the market is still valuing the franchise as a binary biotech, while the settlement effectively extends the period of quasi-exclusivity long enough for the company to compound commercial inertia before the next wave of competition matters.

The more important read-through is to the competitive set: any late-stage or near-commercial rare-disease asset with a similar launch curve may now be judged against a higher bar for durability, not just first-year uptake. If Attruby keeps inflecting while bridge financing risk recedes, the market could begin to price BBIO as a portfolio builder rather than a single-product call option, which tends to compress the discount applied to the pipeline.

The main risk is that the current optimism is front-loading too much of the 2031 runway into the stock today. If the next few quarters show any deceleration in revenue growth, or if the upcoming filings slip into 2027, the narrative can revert quickly because the equity is still hostage to execution rather than diversified earnings. In that sense, the stock’s upside is more about sustaining surprise than delivering one more good quarter.

Contrarian angle: the buyback may be more defensive than the market is interpreting—management could be signaling that the best incremental use of capital is supporting the stock while the pipeline matures, not because the business has fully de-risked. That makes the setup attractive, but also means the multiple is vulnerable if buyback support masks slowing momentum or if investors start demanding clearer evidence that the second and third products can independently move valuation.

Key Decisions for Investors

• Go long BBIO into any post-earnings weakness over the next 1-3 weeks; target a re-rating toward analyst fair value if commercial momentum remains intact, but use a 12-15% hard stop if revenue growth decelerates.
• Sell cash-secured puts on BBIO at strikes ~10-15% below spot for the next 2-4 months to express constructive bias while getting paid for volatility around execution risk.
• Pair trade: long BBIO / short a basket of higher-binary, pre-commercial biotech names over the next 3-6 months; BBIO’s near-term cash generation and buyback support should outperform if the sector de-risks.
• If BBIO rallies on follow-through buying, consider buying downside protection via 3-6 month puts rather than trimming outright; the stock still trades like a momentum biotech, so gap risk remains high if the next catalyst disappoints.
• Monitor the next two quarterly updates closely; if attrition in growth or filing delays show up, reverse the long and short into strength because the market will likely reprice the story back toward pure pipeline optionality.